Cesarean section (C-section) is the most commonly performed major operation in the world. Patients undergoing C-sections are at risk of surgical site infection (SSI) – a common and devastating complication of surgery. Infection rates are particularly high in low- and middle-income countries (LMICs).
Lifebox is working with partners to adapt its surgical infection reduction program – Clean Cut – to improve the safety of C-sections in Ethiopia where the majority of C-sections are essential surgical procedures. In Ethiopia, there is an estimated SSI rate following C-section of 9% and infections and complications following C-sections are estimated to cause 15% of maternal deaths in the country.
From June 2021 to August 2023, Lifebox adapted its surgical infection reduction program – Clean Cut – to specifically improve the safety of C-sections in Ethiopia, where the majority of C-sections are essential surgical procedures. The program was implemented at nine maternity hospitals in Ethiopia as part of a rigorous study to evaluate its impact on C-section care and improve the safety of women undergoing this common operation. Over 10,000 patients have been enrolled and followed across sequential intervention phases.
The Clean Cut for C-Section, a randomized stepped-wedge clinical trial, was effectively implemented over a two-year period across nine maternity hospitals in Ethiopia. The findings were published in JAMA Open in August 2024. The adaptation of Clean Cut for C-sections is part of a randomized control trial called CLEAN-CS.
